Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155)
The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”
